XML 69 R51.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Oct. 06, 2021 | Sep. 30, 2022 | Aug. 31, 2022 | Jan. 31, 2022 | Sep. 30, 2022 | Dec. 31, 2021
Agreements |  |  |  |  |  |
Long-term royalty and commercial payment receivables |  | $ 66,049 |  |  | $ 66,049 | $ 69,075
Contingent consideration under RPAs and CPPAs |  | 75 |  |  | 75 | 8,075
Impairment of long-term royalty receivable |  |  |  |  | 0 | 0
Affitech | Commercial Payment Purchase Agreement |  |  |  |  |  |
Agreements |  |  |  |  |  |
Upfront payment | $ 6,000 |  |  |  |  |
Maximum additional payments upon achievement of regulatory and sales milestones | 20,000 |  |  |  |  |
Long-term royalty and commercial payment receivables | 14,000 |  |  |  |  |
Maximum payable on regulatory milestone | 8,000 |  |  |  |  |
Maximum payable on sales milestone | $ 12,000 |  |  |  |  |
Milestone payment |  | $ 3,000 |  | $ 5,000 |  |
Cash receipts for achievement of contractual milestones |  |  | $ 500 |  |  |
Impairment of long-term royalty receivable |  |  |  |  | 0 | 0
Affitech | Commercial Payment Purchase Agreement | Faricimab |  |  |  |  |  |
Agreements |  |  |  |  |  |
Payments eligible to receive (as a percent) | 0.50% |  |  |  |  |
Commercial payment receivable term | 10 years |  |  |  |  |
Affitech | Commercial Payment Purchase Agreement | VABYSMO |  |  |  |  |  |
Agreements |  |  |  |  |  |
Payments eligible to receive (as a percent) |  | 0.50% |  |  |  |
Commercial payment receivable term |  | 10 years |  |  |  |
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones |  |  |  |  |  |
Agreements |  |  |  |  |  |
Contingent consideration under RPAs and CPPAs | $ 8,000 | $ 0 |  |  | 0 | $ 8,000
Affitech | Commercial Payment Purchase Agreement | Sales milestones |  |  |  |  |  |
Agreements |  |  |  |  |  |
Contingent consideration under RPAs and CPPAs |  | $ 0 |  |  | $ 0 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash receipts for achievement of contractual milestones. + References No definition available. + Details
Name: | xoma_CashReceivedForAchievementOfContractualMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Term of commercial payment receivable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | xoma_CommercialPaymentReceivableTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payments entity eligible to receive as a percentage of net sales. + References No definition available. + Details
Name: | xoma_CommercialSalesReceivablePercentageOnNetSales
Namespace Prefix: | xoma_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements and commercial payment purchase agreements. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum eligible milestone payments receivable upon achievement of sales and/or regulatory milestones. + References No definition available. + Details
Name: | xoma_EligibleMilestonePaymentsReceivableUponAchievementOfRegulatoryAndSalesMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty and commercial rights receivables, non current. + References No definition available. + Details
Name: | xoma_LongTermRightsReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount payable on regulatory milestone. + References No definition available. + Details
Name: | xoma_MaximumPayableOnRegulatoryMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable on sales milestone. + References No definition available. + Details
Name: | xoma_MaximumPayableOnSalesMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payment during the period. + References No definition available. + Details
Name: | xoma_MilestonePayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for initial payment under agreement. + References No definition available. + Details
Name: | xoma_UpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_FaricimabProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationSalesMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |